Teacher Retirement System of Texas Boosts Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Teacher Retirement System of Texas boosted its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 19.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 9,241 shares of the company’s stock after buying an additional 1,499 shares during the quarter. Teacher Retirement System of Texas’ holdings in Axsome Therapeutics were worth $782,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Axsome Therapeutics by 4.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 322,596 shares of the company’s stock valued at $28,992,000 after buying an additional 12,778 shares in the last quarter. FMR LLC raised its stake in Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after acquiring an additional 185,951 shares during the period. BNP Paribas Financial Markets lifted its holdings in Axsome Therapeutics by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 13,733 shares of the company’s stock valued at $1,234,000 after purchasing an additional 5,737 shares in the last quarter. Captrust Financial Advisors bought a new position in shares of Axsome Therapeutics in the third quarter worth approximately $514,000. Finally, Fred Alger Management LLC purchased a new stake in shares of Axsome Therapeutics in the third quarter worth $851,000. Institutional investors own 81.49% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on AXSM shares. Cantor Fitzgerald restated an “overweight” rating and set a $153.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Royal Bank of Canada boosted their price objective on Axsome Therapeutics from $143.00 to $192.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. Truist Financial increased their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Robert W. Baird boosted their price target on Axsome Therapeutics from $132.00 to $160.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Axsome Therapeutics in a report on Thursday, March 6th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $167.64.

Axsome Therapeutics Trading Down 2.7 %

Shares of AXSM opened at $118.53 on Monday. The stock has a market capitalization of $5.78 billion, a PE ratio of -19.79 and a beta of 1.00. The company’s fifty day moving average is $119.67 and its 200 day moving average is $101.22. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Sell-side analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.